Cancer vaccines have long carried a tantalising promise: instead of broadly attacking cancer cells, could treatment train the immune system to recognise and destroy the specific cancer threatening a patient? That idea has taken a major step forward with positive results from a large Phase 3 trial of a personalised mRNA-based cancer therapy developed by Moderna and Merck.
